As a tumor suppressor, CYLD was identified as mutated in familial cylindromatosis and loss of CYLD has also been implicated in several other malignancies, such as colon and hepatocellular carcinomas, multiple myeloma, melanoma, and breast cancer16,17. Here, CYLD is linked to plasma cell myeloma.